# SAM #NOI-OLAO-CC-27-000121

NIH Clinical Center intent to sole-source laboratory instruments for pathogen research

**Buyer:** National Institutes of Health
**Posted:** October 08, 2026
**Respond By:** October 23, 2026
**Identifier:** NOI-OLAO-CC-27-000121
**NAICS:** 334516

NIH Clinical Center plans a sole-source acquisition of three laboratory instruments for research on transfusion-transmitted pathogens.
- **Agency and procurement approach**
  - The National Institutes of Health (NIH), Clinical Center (NIH-CC), Department of Transfusion Medicine (DTM), Infectious Diseases Section, intends to acquire the instruments from Fisher Scientific.
  - This is a notice of intent under other-than-full-and-open competition, not a request for proposals. NIH invites capability statements from responsible sources.
- **Instruments sought**
  - One real-time PCR system, one automated nucleic acid extractor, and one microvolume spectrophotometer; specific models, part numbers, and quantities are not provided.
  - The notice names Fisher Scientific as the intended vendor; attachment filenames also reference Thermo Fisher.
- **Purpose and requirements**
  - Support development, optimization, and validation of diagnostic assays for hepatitis viruses and other transfusion-transmitted pathogens.
  - Provide accurate, reproducible analysis of viral and host nucleic acids with low-to-moderate throughput, rapid turnaround, flexible run configurations, and cost-efficient operation.
  - Support an integrated workflow for extraction, amplification, quantification, and data analysis, while remaining easy to use, compatible with existing laboratory methods, and suitable for a CLIA-certified environment.

### Description

<p>This is a Notice of Intent, not a request for proposal.&nbsp; The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with the following vendor: Fisher Scientific.</p>

<p>Acquisition Description:</p>

<p>The NIH Clinical Center, Department of Transfusion Medicine (DTM), Infectious Diseases Section requires acquisition of a 1) Real-Time PCR System, 2) an Automated Nucleic Acid Extractor and 3) a microvolume spectrophotometer to support clinical research and the development, optimization, and validation of diagnostic assays for hepatitis viruses and other transfusion-transmitted pathogens.</p>

<p>The required system must support generation of high-quality quantification data from clinical specimens, including viral RNA/DNA and host-derived nucleic acids. The instrument must enable applications such as targeted genome amplification, work with a wider dynamic detection range, support the library prep for viral genome sequencing, and assay development workflows necessary for evaluating test performance and refining diagnostic methods prior to implementation in a clinical testing environment.</p>

<p>The system must meet the following functional and operational requirements:</p>

<ul>
	<li><strong>High data accuracy and reproducibility</strong> to ensure reliable detection of viral variants and evaluation of assay performance;</li>
	<li><strong>Low- to moderate-throughput capability</strong> appropriate for assay development, pilot studies, and validation activities involving smaller sample sets;</li>
	<li><strong>Rapid turnaround times</strong> to support iterative testing and optimization of clinical assays;</li>
	<li><strong>Flexible run configurations</strong> that allow efficient processing of varying sample volumes without excess capacity;</li>
	<li><strong>Cost-efficient operation</strong>, including the ability to minimize per-run and per-sample costs for pathogen detection;</li>
	<li><strong>Integrated and streamlined workflows</strong>, including nucleic acid extraction, amplification, quantification and data analysis within a platform from the same vendor to reduce complexity and variability;</li>
	<li><strong>Ease of use and standardized operation</strong>, supporting reproducibility and implementation in a clinical laboratory environment;</li>
	<li><strong>Compatibility</strong> with established nucleic acid preparation and amplification methods and existing laboratory workflows.</li>
	<li><strong>The flexibility</strong> to be using the systems in a CLIA certified environment.&nbsp;</li>
</ul>

<p>The statutory authority for this sole source requirement is 41 U.S.C. 253(c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL.&nbsp; All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-OLAO-CC-27-000121) by 12:00 PM eastern standard time on 10/23/2026 to: valerie.gregorio@nih.gov.</p>

<p>All responses received by the closing date of this synopsis will be considered by the Government.&nbsp; A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.</p>

<p></p>

<p></p>

[View original listing](https://sam.gov/opp/bf6b20798a274eb2936262d401e097a7/view)